A citation-based method for searching scientific literature

Martin J van den Bent, C Mircea S Tesileanu, Wolfgang Wick, Marc Sanson, Alba Ariela Brandes, Paul M Clement, Sarah Erridge, Michael A Vogelbaum, Anna K Nowak, Jean Français Baurain, Warren P Mason, Helen Wheeler, Olivier L Chinot, Sanjeev Gill, Matthew Griffin, Leland Rogers, Walter Taal, Roberta Rudà, Michael Weller, Catherine McBain, Jaap Reijneveld, Roelien H Enting, Francesca Caparrotti, Thierry Lesimple, Susan Clenton, Anja Gijtenbeek, Elizabeth Lim, Ulrich Herrlinger, Peter Hau, Frederic Dhermain, Iris de Heer, Kenneth Aldape, Robert B Jenkins, Hendrikus Jan Dubbink, Johan M Kros, Pieter Wesseling, Sarah Nuyens, Vassilis Golfinopoulos, Thierry Gorlia, Pim French, Brigitta G Baumert. Lancet Oncol 2021
Times Cited: 44







List of co-cited articles
306 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma.
Jan C Buckner, Edward G Shaw, Stephanie L Pugh, Arnab Chakravarti, Mark R Gilbert, Geoffrey R Barger, Stephen Coons, Peter Ricci, Dennis Bullard, Paul D Brown,[...]. N Engl J Med 2016
548
47

Comprehensive Genomic Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma.
Erica H Bell, Peixin Zhang, Edward G Shaw, Jan C Buckner, Geoffrey R Barger, Dennis E Bullard, Minesh P Mehta, Mark R Gilbert, Paul D Brown, Keith J Stelzer,[...]. J Clin Oncol 2020
63
45

The 2021 WHO Classification of Tumors of the Central Nervous System: a summary.
David N Louis, Arie Perry, Pieter Wesseling, Daniel J Brat, Ian A Cree, Dominique Figarella-Branger, Cynthia Hawkins, H K Ng, Stefan M Pfister, Guido Reifenberger,[...]. Neuro Oncol 2021
45

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Roger Stupp, Warren P Mason, Martin J van den Bent, Michael Weller, Barbara Fisher, Martin J B Taphoorn, Karl Belanger, Alba A Brandes, Christine Marosi, Ulrich Bogdahn,[...]. N Engl J Med 2005
38

Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951.
Martin J van den Bent, Alba A Brandes, Martin J B Taphoorn, Johan M Kros, Mathilde C M Kouwenhoven, Jean-Yves Delattre, Hans J J A Bernsen, Marc Frenay, Cees C Tijssen, Wolfgang Grisold,[...]. J Clin Oncol 2013
736
36

Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study.
Martin J van den Bent, Brigitta Baumert, Sara C Erridge, Michael A Vogelbaum, Anna K Nowak, Marc Sanson, Alba Ariela Brandes, Paul M Clement, Jean Francais Baurain, Warren P Mason,[...]. Lancet 2017
197
36

Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.
Gregory Cairncross, Meihua Wang, Edward Shaw, Robert Jenkins, David Brachman, Jan Buckner, Karen Fink, Luis Souhami, Normand Laperriere, Walter Curran,[...]. J Clin Oncol 2013
683
36

The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.
David N Louis, Arie Perry, Guido Reifenberger, Andreas von Deimling, Dominique Figarella-Branger, Webster K Cavenee, Hiroko Ohgaki, Otmar D Wiestler, Paul Kleihues, David W Ellison. Acta Neuropathol 2016
36

MGMT gene silencing and benefit from temozolomide in glioblastoma.
Monika E Hegi, Annie-Claire Diserens, Thierry Gorlia, Marie-France Hamou, Nicolas de Tribolet, Michael Weller, Johan M Kros, Johannes A Hainfellner, Warren Mason, Luigi Mariani,[...]. N Engl J Med 2005
34

Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.
Brigitta G Baumert, Monika E Hegi, Martin J van den Bent, Andreas von Deimling, Thierry Gorlia, Khê Hoang-Xuan, Alba A Brandes, Guy Kantor, Martin J B Taphoorn, Mohamed Ben Hassel,[...]. Lancet Oncol 2016
268
31

Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas.
Daniel J Brat, Roel G W Verhaak, Kenneth D Aldape, W K Alfred Yung, Sofie R Salama, Lee A D Cooper, Esther Rheinbay, C Ryan Miller, Mark Vitucci, Olena Morozova,[...]. N Engl J Med 2015
29

Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial.
M J van den Bent, D Afra, O de Witte, M Ben Hassel, S Schraub, K Hoang-Xuan, P-O Malmström, L Collette, M Piérart, R Mirimanoff,[...]. Lancet 2005
609
27

IDH1 and IDH2 mutations in gliomas.
Hai Yan, D Williams Parsons, Genglin Jin, Roger McLendon, B Ahmed Rasheed, Weishi Yuan, Ivan Kos, Ines Batinic-Haberle, Siân Jones, Gregory J Riggins,[...]. N Engl J Med 2009
27

Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors.
Jeanette E Eckel-Passow, Daniel H Lachance, Annette M Molinaro, Kyle M Walsh, Paul A Decker, Hugues Sicotte, Melike Pekmezci, Terri Rice, Matt L Kosel, Ivan V Smirnov,[...]. N Engl J Med 2015
27

cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas.
Daniel J Brat, Kenneth Aldape, Howard Colman, Dominique Figrarella-Branger, Gregory N Fuller, Caterina Giannini, Eric C Holland, Robert B Jenkins, Bette Kleinschmidt-DeMasters, Takashi Komori,[...]. Acta Neuropathol 2020
199
25

EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood.
Michael Weller, Martin van den Bent, Matthias Preusser, Emilie Le Rhun, Jörg C Tonn, Giuseppe Minniti, Martin Bendszus, Carmen Balana, Olivier Chinot, Linda Dirven,[...]. Nat Rev Clin Oncol 2021
337
22

cIMPACT-NOW update 3: recommended diagnostic criteria for "Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV".
Daniel J Brat, Kenneth Aldape, Howard Colman, Eric C Holland, David N Louis, Robert B Jenkins, B K Kleinschmidt-DeMasters, Arie Perry, Guido Reifenberger, Roger Stupp,[...]. Acta Neuropathol 2018
405
22

cIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading.
David N Louis, Pieter Wesseling, Kenneth Aldape, Daniel J Brat, David Capper, Ian A Cree, Charles Eberhart, Dominique Figarella-Branger, Maryam Fouladi, Gregory N Fuller,[...]. Brain Pathol 2020
222
22

Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH.
J Gregory Cairncross, Meihua Wang, Robert B Jenkins, Edward G Shaw, Caterina Giannini, David G Brachman, Jan C Buckner, Karen L Fink, Luis Souhami, Normand J Laperriere,[...]. J Clin Oncol 2014
281
20

CODEL: phase III study of RT, RT + TMZ, or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial study design.
Kurt A Jaeckle, Karla V Ballman, Martin van den Bent, Caterina Giannini, Evanthia Galanis, Paul D Brown, Robert B Jenkins, J Gregory Cairncross, Wolfgang Wick, Michael Weller,[...]. Neuro Oncol 2021
30
30

Mechanisms and therapeutic implications of hypermutation in gliomas.
Mehdi Touat, Yvonne Y Li, Adam N Boynton, Liam F Spurr, J Bryan Iorgulescu, Craig L Bohrson, Isidro Cortes-Ciriano, Cristina Birzu, Jack E Geduldig, Kristine Pelton,[...]. Nature 2020
220
18

Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma.
James R Perry, Normand Laperriere, Christopher J O'Callaghan, Alba A Brandes, Johan Menten, Claire Phillips, Michael Fay, Ryo Nishikawa, J Gregory Cairncross, Wilson Roa,[...]. N Engl J Med 2017
513
18


A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01).
Carmen Balana, Maria Angeles Vaz, Juan Manuel Sepúlveda, Carlos Mesia, Sonia Del Barco, Estela Pineda, Jose Muñoz-Langa, Anna Estival, Ramón de Las Peñas, Jose Fuster,[...]. Neuro Oncol 2020
40
17

Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide.
Wolfgang Wick, Patrick Roth, Christian Hartmann, Peter Hau, Makoto Nakamura, Florian Stockhammer, Michael C Sabel, Antje Wick, Susanne Koeppen, Ralf Ketter,[...]. Neuro Oncol 2016
132
15

An integrated genomic analysis of human glioblastoma multiforme.
D Williams Parsons, Siân Jones, Xiaosong Zhang, Jimmy Cheng-Ho Lin, Rebecca J Leary, Philipp Angenendt, Parminder Mankoo, Hannah Carter, I-Mei Siu, Gary L Gallia,[...]. Science 2008
15

Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Roger Stupp, Sophie Taillibert, Andrew Kanner, William Read, David Steinberg, Benoit Lhermitte, Steven Toms, Ahmed Idbaih, Manmeet S. Ahluwalia, Karen Fink,[...]. JAMA 2017
979
15

A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844.
A B Karim, B Maat, R Hatlevoll, J Menten, E H Rutten, D G Thomas, F Mascarenhas, J C Horiot, L M Parvinen, M van Reijn,[...]. Int J Radiat Oncol Biol Phys 1996
456
13

Phase 2 Study of a Temozolomide-Based Chemoradiation Therapy Regimen for High-Risk, Low-Grade Gliomas: Long-Term Results of Radiation Therapy Oncology Group 0424.
Barbara J Fisher, Stephanie L Pugh, David R Macdonald, Arnab Chakravatri, Glenn J Lesser, Sherry Fox, C Leland Rogers, Maria Werner-Wasik, Thomas Doyle, Jean-Paul Bahary,[...]. Int J Radiat Oncol Biol Phys 2020
22
27

Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma.
Brett E Johnson, Tali Mazor, Chibo Hong, Michael Barnes, Koki Aihara, Cory Y McLean, Shaun D Fouse, Shogo Yamamoto, Hiroki Ueda, Kenji Tatsuno,[...]. Science 2014
894
13

Novel, improved grading system(s) for IDH-mutant astrocytic gliomas.
Mitsuaki Shirahata, Takahiro Ono, Damian Stichel, Daniel Schrimpf, David E Reuss, Felix Sahm, Christian Koelsche, Annika Wefers, Annekathrin Reinhardt, Kristin Huang,[...]. Acta Neuropathol 2018
177
13

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.
Lenny Dang, David W White, Stefan Gross, Bryson D Bennett, Mark A Bittinger, Edward M Driggers, Valeria R Fantin, Hyun Gyung Jang, Shengfang Jin, Marie C Keenan,[...]. Nature 2009
13

European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas.
Michael Weller, Martin van den Bent, Jörg C Tonn, Roger Stupp, Matthias Preusser, Elizabeth Cohen-Jonathan-Moyal, Roger Henriksson, Emilie Le Rhun, Carmen Balana, Olivier Chinot,[...]. Lancet Oncol 2017
601
13

A vaccine targeting mutant IDH1 in newly diagnosed glioma.
Michael Platten, Lukas Bunse, Antje Wick, Theresa Bunse, Lucian Le Cornet, Inga Harting, Felix Sahm, Khwab Sanghvi, Chin Leng Tan, Isabel Poschke,[...]. Nature 2021
110
13

Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions.
Patrick Y Wen, Michael Weller, Eudocia Quant Lee, Brian M Alexander, Jill S Barnholtz-Sloan, Floris P Barthel, Tracy T Batchelor, Ranjit S Bindra, Susan M Chang, E Antonio Chiocca,[...]. Neuro Oncol 2020
287
13

Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial.
Ulrich Herrlinger, Theophilos Tzaridis, Frederic Mack, Joachim Peter Steinbach, Uwe Schlegel, Michael Sabel, Peter Hau, Rolf-Dieter Kortmann, Dietmar Krex, Oliver Grauer,[...]. Lancet 2019
242
13

Ivosidenib in Isocitrate Dehydrogenase 1-Mutated Advanced Glioma.
Ingo K Mellinghoff, Benjamin M Ellingson, Mehdi Touat, Elizabeth Maher, Macarena I De La Fuente, Matthias Holdhoff, Gregory M Cote, Howard Burris, Filip Janku, Robert J Young,[...]. J Clin Oncol 2020
92
13

Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial.
Annika Malmström, Bjørn Henning Grønberg, Christine Marosi, Roger Stupp, Didier Frappaz, Henrik Schultz, Ufuk Abacioglu, Björn Tavelin, Benoit Lhermitte, Monika E Hegi,[...]. Lancet Oncol 2012
771
13

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Roger Stupp, Monika E Hegi, Warren P Mason, Martin J van den Bent, Martin J B Taphoorn, Robert C Janzer, Samuel K Ludwin, Anouk Allgeier, Barbara Fisher, Karl Belanger,[...]. Lancet Oncol 2009
13

Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.
Patrick Y Wen, David R Macdonald, David A Reardon, Timothy F Cloughesy, A Gregory Sorensen, Evanthia Galanis, John Degroot, Wolfgang Wick, Mark R Gilbert, Andrew B Lassman,[...]. J Clin Oncol 2010
13

Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802.
Edward G Shaw, Meihua Wang, Stephen W Coons, David G Brachman, Jan C Buckner, Keith J Stelzer, Geoffrey R Barger, Paul D Brown, Mark R Gilbert, Minesh P Mehta. J Clin Oncol 2012
220
11

Survival of diffuse astrocytic glioma, IDH1/2 wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria.
C Mircea S Tesileanu, Linda Dirven, Maarten M J Wijnenga, Johan A F Koekkoek, Arnaud J P E Vincent, Hendrikus J Dubbink, Peggy N Atmodimedjo, Johan M Kros, Sjoerd G van Duinen, Marion Smits,[...]. Neuro Oncol 2020
76
11

Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma.
C Mircea S Tesileanu, Martin J van den Bent, Marc Sanson, Wolfgang Wick, Alba A Brandes, Paul M Clement, Sara C Erridge, Michael A Vogelbaum, Anna K Nowak, Jean F Baurain,[...]. Neuro Oncol 2021
15
33

Longitudinal molecular trajectories of diffuse glioma in adults.
Floris P Barthel, Kevin C Johnson, Frederick S Varn, Anzhela D Moskalik, Georgette Tanner, Emre Kocakavuk, Kevin J Anderson, Olajide Abiola, Kenneth Aldape, Kristin D Alfaro,[...]. Nature 2019
179
11

Comparison of a strategy favoring early surgical resection vs a strategy favoring watchful waiting in low-grade gliomas.
Asgeir S Jakola, Kristin S Myrmel, Roar Kloster, Sverre H Torp, Sigurd Lindal, Geirmund Unsgård, Ole Solheim. JAMA 2012
397
11

CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016.
Quinn T Ostrom, Gino Cioffi, Haley Gittleman, Nirav Patil, Kristin Waite, Carol Kruchko, Jill S Barnholtz-Sloan. Neuro Oncol 2019
11

Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma.
Houtan Noushmehr, Daniel J Weisenberger, Kristin Diefes, Heidi S Phillips, Kanan Pujara, Benjamin P Berman, Fei Pan, Christopher E Pelloski, Erik P Sulman, Krishna P Bhat,[...]. Cancer Cell 2010
11

The somatic genomic landscape of glioblastoma.
Cameron W Brennan, Roel G W Verhaak, Aaron McKenna, Benito Campos, Houtan Noushmehr, Sofie R Salama, Siyuan Zheng, Debyani Chakravarty, J Zachary Sanborn, Samuel H Berman,[...]. Cell 2013
11

Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial.
David A Reardon, Alba A Brandes, Antonio Omuro, Paul Mulholland, Michael Lim, Antje Wick, Joachim Baehring, Manmeet S Ahluwalia, Patrick Roth, Oliver Bähr,[...]. JAMA Oncol 2020
426
11

Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial.
Ingo K Mellinghoff, Marta Penas-Prado, Katherine B Peters, Howard A Burris, Elizabeth A Maher, Filip Janku, Gregory M Cote, Macarena I de la Fuente, Jennifer L Clarke, Benjamin M Ellingson,[...]. Clin Cancer Res 2021
47
11


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.